The impact of expanded access to direct acting antivirals for Hepatitis C virus on patient outcomes in Canada.

Expanding DAA access was associated with a drop in HCV-related hospitalizations in the overall Canadian population coinciding with the 2014 policy change. In light of the time required for HCV-related complications to manifest, continued ongoing research examining the real-world effectiveness of DAAs is required.